FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it

Regeneron $REGN says the FDA has rejected their application to sell a pre-filled syringe with Eylea, delaying a supplemental add-on that the biotech wants to safeguard its big blockbuster franchise from a rival. But the company was quick to spell out the reasons for the CRL, asserting that it can get things in line for regulators by early 2019.